Company Analysis

Lantern Pharma Inc. (LTRN)

Nasdaq: LTRN · Pharmaceutical Preparations · Dallas, TX · filing with the SEC since 2019
Grade5.5
◀ Past 6.0● Present 5.3▶ Future 5.4
6 est.

Filings

170 filings since 2017 beside 92 insider forms · Non-accelerated filer and smaller reporting company · read from EDGAR on Nov 13, 2026
Due nextNon-accelerated filer and smaller reporting company
10-Q Quarterly report for the quarter ending Sep 30, 2026Non-accelerated filers and smaller reporting companies have 45 days after the quarter ends; quarter ends are taken to the month end. by Nov 14, 2026
10-K Annual report for the fiscal year ending Dec 31, 2026Non-accelerated filers and smaller reporting companies have 90 days after the fiscal year ends. by Mar 31, 2027

A deadline is the latest date the SEC's rules allow for its filer category. It is not a forecast of the day the company files. Last time, the results release (8-K item 2.02) came 45 days after the quarter ended. The proxy statement was last filed Oct 19, 2026.

Filings a yearinsider forms included
261352618423939
20192020202120222023202420252026

2026 counts to Nov 13, 2026.

Listing warning from its exchange (8-K item 3.01): 1 time in the last 36 months, the newest Oct 1, 2026.Officer or director change (8-K item 5.02): 3 times in the last 36 months, the newest Jul 29, 2025.SEC letters: 2 in the last 36 months, the newest Jun 6, 2024.
Insider forms 92

Insider forms (3, 4, 5 and 144) are counted each year but not listed here; the people and their trades are on the Ownership tab.

FiledFormWhat it is, in plain wordsPeriodAsk
Oct 21, 2026 ARS Annual report to shareholders Dec 31, 2025
Oct 19, 2026 DEF 14A Proxy statement
Oct 13, 2026 SCHEDULE 13G/A Large holder update, amended
Oct 8, 2026 PRE 14A Preliminary proxy statement
Oct 1, 2026 8-K item 3.01 Listing warning from its exchange · Current report Sep 25, 2026
Sep 30, 2026 8-K items 1.01, 3.02, 9.01 Major agreement signed; Shares sold without registration · Current report Sep 28, 2026
Sep 30, 2026 424B5 Shelf offering
Sep 24, 2026 8-K items 7.01, 9.01 Investor disclosure (Regulation FD) · Current report Sep 23, 2026
Sep 23, 2026 8-K items 7.01, 9.01 Investor disclosure (Regulation FD) · Current report
Aug 14, 2026 8-K items 2.02, 7.01, 9.01 Results released; Investor disclosure (Regulation FD) · Current report
Aug 14, 2026 10-Q Quarterly report Jun 30, 2026
Aug 4, 2026 SCHEDULE 13G Large holder notice
Aug 3, 2026 8-K items 7.01, 9.01 Investor disclosure (Regulation FD) · Current report
Jul 23, 2026 SCHEDULE 13G/A Large holder update, amended
Jun 18, 2026 EFFECT Registration effective
Jun 12, 2026 S-1 Listing registration
Jun 2, 2026 8-K items 7.01, 9.01 Investor disclosure (Regulation FD) · Current report Jun 1, 2026
May 21, 2026 D Private placement notice
May 15, 2026 SCHEDULE 13D/A Activist holder update, amended
May 15, 2026 8-K items 2.02, 9.01 Results released · Current report
May 15, 2026 10-Q Quarterly report Mar 31, 2026
May 14, 2026 8-K items 1.01, 3.02, 8.01, 9.01 Major agreement signed; Shares sold without registration; Other event · Current report May 12, 2026
May 14, 2026 424B5 Shelf offering
Apr 30, 2026 10-K/A Annual report, amended Dec 31, 2025
Apr 16, 2026 SCHEDULE 13D/A Activist holder update, amended
Apr 10, 2026 8-K items 7.01, 9.01 Investor disclosure (Regulation FD) · Current report Apr 9, 2026
Apr 3, 2026 SCHEDULE 13G Large holder notice
Mar 30, 2026 424B5 Shelf offering
Mar 30, 2026 10-K Annual report Dec 31, 2025
Mar 30, 2026 8-K items 2.02, 7.01, 9.01 Results released; Investor disclosure (Regulation FD) · Current report
Feb 23, 2026 SCHEDULE 13D/A Activist holder update, amended
Jan 23, 2026 8-K items 7.01, 9.01 Investor disclosure (Regulation FD) · Current report Jan 22, 2026
Nov 13, 2025 8-K items 2.02, 7.01, 9.01 Results released; Investor disclosure (Regulation FD) · Current report
Nov 12, 2025 10-Q Quarterly report Sep 30, 2025
Sep 23, 2025 8-K item 5.07 Shareholder vote · Current report Sep 19, 2025
Aug 13, 2025 8-K items 2.02, 9.01 Results released · Current report
Aug 13, 2025 10-Q Quarterly report Jun 30, 2025
Aug 11, 2025 ARS Annual report to shareholders Dec 31, 2024
Aug 8, 2025 DEF 14A Proxy statement
Jul 29, 2025 8-K items 5.02, 5.03, 9.01 Officer or director change; Charter, bylaw or fiscal-year change · Current report Jul 24, 2025
40 of 170 shown

Every row opens the filing on EDGAR. The plain words are the site's own for each form and each 8-K item; the complete history, insider forms included, is on EDGAR.

SI Assistanton LTRN · research, not advice